|Articles|June 1, 2001

NSAIDs affect nervous system

Widely prescribed pain killers that provide relief with minimal side effects may have more pain-relieving properties than previously identified. A new study funded by the National Institute of Neurological Disorders and Stroke shows that non-steroidal anti-inflammatory drugs not only relieve pain at the local site of inflammation, but in fact affect the entire central nervous system.

Widely prescribed pain killers that provide relief with minimal side effects may have more pain-relieving properties than previously identified. A new study funded by the National Institute of Neurological Disorders and Stroke shows that non-steroidal anti-inflammatory drugs not only relieve pain at the local site of inflammation, but in fact affect the entire central nervous system.

NSAIDs reduce sensitivity of nerves in the central nervous system by inhibiting production of the COX-2 enzyme responsible for pain and inflammation.

A research team led by Clifford J. Woolf at Massachusetts General Hospital in Boston used an animal model to study COX-2's role in inflammatory pain. When inflammation occurred, researchers found COX-2 throughout the central nervous system, as well as at the local site of inflammation. They also found that inhibiting COX-2 production within the spinal cord and brain decreased pain and reduced hypersensitivity to normal sensations such as touch. Researchers now believe the widespread distribution of COX-2 within the central nervous system may contribute to the muscle and joint pain, depression, lethargy and loss of appetite that often occur with inflammation and infection.

"The findings indicate new treatment options for arthritis and other inflammatory pain conditions," said Cheryl A. Kitt, program director for pain research at the NINDS. "Targeting the central nervous system when using NSAIDs, rather than the specific peripheral pain site, may result in more effective pain relief." PR


Related to this article

Pharmaceutical Executive Daily
The FDA approves Roche’s Tecentriq for a subset of colon cancer patients, TRexBio and Retension Pharmaceuticals price new IPOs, and a Pharmaceutical Executive feature examines what it takes to turn precision medicine’s biological gains into deliverable therapies.
Naoki Okamura: Post-Patent Plan and Purpose
Astellas CEO Naoki Okamura is putting a “patient axis” operating model, a broader portfolio of strategic brands and a new generation of science to work in the company’s bid to return to record growth.